Completed PHASE4 INTERVENTIONAL NCT00094549

Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder

Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder

Sponsor: Eli Lilly and Company

Interventions divalproex sodium olanzapine placebo

Updated 6 times since 2017 Last updated: Jan 24, 2007 Started: Oct 31, 2004 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Bipolar Disorder, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 6 data snapshots since 2004. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Baltimore, United States , Bellevue, United States , Beverly Hills, United States , Boyton Beach, United States , Brooklyn, United States , Bucharest, Romania , Buffalo, United States , Caguas, Puerto Rico , Charleston, United States and 32 more locations